Stelara Market, By Indication (Moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy, Psoriatic Arthritis (PsA), Crohns disease (CD), and Ulcerative Colitis), By Route of Administration (Subcutaneous Injection,

The Global Stelara Market is estimated to be valued at USD 9,532.3 million in 2025 and is expected to reach USD 2,963.1 million by 2032, exhibiting a compound annual growth rate (CAGR) of -15.4% from 2025 to 2032.

The global Stelara market, centered around ustekinumab, a monoclonal antibody therapeutic developed by Johnson & Johnson's Janssen Pharmaceuticals, remains a key segment within the pharmaceutical industry. Stelara was initially recognized as a groundbreaking treatment for various immune-mediated inflammatory diseases, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The biologic medication works by targeting specific proteins in the immune system, particularly interleukin-12 and interleukin-23, which play crucial roles in inflammatory processes. However, despite its initial success, the market has faced a decline, driven by the increasing availability of biosimilars, high treatment costs, and regulatory complexities. The slow growth and negative compound annual growth rate (CAGR) reflect several challenges within the market. While the prevalence of autoimmune disorders continues to rise globally, the adoption of Stelara has been hindered by increasing competition from more affordable alternatives. Additionally, concerns over the high cost of Stelara treatment limit its accessibility, particularly in price-sensitive markets. As healthcare systems focus on cost-effective treatment options, Stelara’s role in managing chronic inflammatory conditions has become more restrained.

Market Dynamics:

The global Stelara market has experienced a slow growth trajectory, driven by several factors, including the rising prevalence of autoimmune and inflammatory diseases such as psoriasis, inflammatory bowel disease, and psoriatic arthritis. While these conditions affect millions of patients globally, the market’s expansion has been constrained by several challenges. Despite the continued adoption of biologic therapies over conventional treatments due to their superior efficacy, the high cost of Stelara has limited accessibility, especially in price-sensitive markets.

The market’s growth has also been hindered by increasing competition from biosimilars following the expiration of Stelara’s patent, which has led to reduced market share and price pressure. Moreover, stringent regulatory requirements for biologic approvals result in long development timelines and substantial investment needs, further slowing market momentum.

Although continuous research and development efforts for new therapeutic indications and improved formulations offer some potential, the market's overall growth remains subdued, with a negative CAGR. Expanding healthcare infrastructure in emerging markets and favorable reimbursement policies in developed countries could provide limited opportunities, but these are offset by the broader market pressures. Additionally, strategic partnerships and technological advancements in drug delivery systems and personalized medicine offer potential avenues for market expansion, though these remain constrained by the overarching challenges of cost and competition from biosimilars.

Key Features of the Study:

• This report provides an in-depth analysis of the global Stelara market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Stelara market based on the following parameters: company highlights, product portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Johnson & Johnson (Janssen Pharmaceuticals), biosimilar manufacturers, generic pharmaceutical companies, and other biologic therapy developers.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global Stelara market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Stelara market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy
• Psoriatic Arthritis (PsA)
• Crohn’s disease (CD)
• Ulcerative Colitis
• Route Of Administration Insights (Revenue, USD Mn, 2020 - 2032)
• Subcutaneous Injection
• Intravenous Infusion
• Strength Insights (Revenue, USD Mn, 2020 - 2032)
• 45 mg/0.5 mL or 90 mg/mL
• 45 mg/0.5 mL
• Dosage Form Insights (Revenue, USD Mn, 2020 - 2032)
• single-dose prefilled syringe
• single-dose vial
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Infusion centers
• Others (Outpatient Settings, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Johnson & Johnson Services, Inc.

Show more